PURPOSE: The aim of this systematic review was to identify the interventions used to treat obstructive events, whether thrombotic or non-thrombotic, in long-term central venous catheters (LT-CVC) in cancer patients. METHODS: This review included clinical trials and observational studies reporting the drugs used to treat obstructive catheter events in cancer patients. The authors developed specific search strategies for CINAHL, Cochrane CENTRAL, LILACS, PubMed, Scopus, Web of Science, Google Scholar, Open Grey, and ProQuest. The authors evaluated methodological quality of included studies using criteria from Cochrane's Collaboration Tool and the Methodological Index for non-randomized studies (MINORS). The quality of evidence was analyzed by using GRADE's software. RESULTS: More than 9000 articles were found across the databases. After duplicates removed, the studies were selected in 2 phases. After that, only 15 studies were included. The drugs used to restoration of catheter function were urokinase (53.3%), alteplase (20%), tenecteplase (13.3%), reteplase (6.7%), recombinant urokinase (6.7%), and staphylokinase (6.7%). The results of meta-analysis of 14 studies showed an overall restoration rate of ~ 84%. The drug type meta-analysis demonstrates a success rate of ~ 84%, ~ 92%, and ~ 84% for urokinase, alteplase, and tenecteplase groups, respectively. The main methodological problem in included articles concerns the sample. The quality of evidence ranged from very low to high. CONCLUSION: The most common interventions used to treat thrombotic catheter occlusion in cancer patients were urokinase and alteplase. No evidence was found about the treatment for non-thrombotic occlusion, thus elucidating an important gap to be investigated.
PURPOSE: The aim of this systematic review was to identify the interventions used to treat obstructive events, whether thrombotic or non-thrombotic, in long-term central venous catheters (LT-CVC) in cancerpatients. METHODS: This review included clinical trials and observational studies reporting the drugs used to treat obstructive catheter events in cancerpatients. The authors developed specific search strategies for CINAHL, Cochrane CENTRAL, LILACS, PubMed, Scopus, Web of Science, Google Scholar, Open Grey, and ProQuest. The authors evaluated methodological quality of included studies using criteria from Cochrane's Collaboration Tool and the Methodological Index for non-randomized studies (MINORS). The quality of evidence was analyzed by using GRADE's software. RESULTS: More than 9000 articles were found across the databases. After duplicates removed, the studies were selected in 2 phases. After that, only 15 studies were included. The drugs used to restoration of catheter function were urokinase (53.3%), alteplase (20%), tenecteplase (13.3%), reteplase (6.7%), recombinant urokinase (6.7%), and staphylokinase (6.7%). The results of meta-analysis of 14 studies showed an overall restoration rate of ~ 84%. The drug type meta-analysis demonstrates a success rate of ~ 84%, ~ 92%, and ~ 84% for urokinase, alteplase, and tenecteplase groups, respectively. The main methodological problem in included articles concerns the sample. The quality of evidence ranged from very low to high. CONCLUSION: The most common interventions used to treat thrombotic catheter occlusion in cancerpatients were urokinase and alteplase. No evidence was found about the treatment for non-thrombotic occlusion, thus elucidating an important gap to be investigated.
Authors: William D Haire; Steven R Deitcher; Kathleen M Mullane; Michael R Jaff; Carolyn M Firszt; Gregory A Schulz; Debra M Schuerr; Lewis B Schwartz; Tamyra L Mouginis; R Phillip Barton Journal: Thromb Haemost Date: 2004-09 Impact factor: 5.249
Authors: Stephan Moll; Peter Kenyon; Luigi Bertoli; James De Maio; Howard Homesley; Steven R Deitcher Journal: J Clin Oncol Date: 2006-07-01 Impact factor: 44.544
Authors: Steven R Deitcher; Giuseppe Fraschini; Jonathan Himmelfarb; Earl Schuman; Thomas J Smith; Gregory A Schulz; Carolyn M Firszt; Tamyra L Mouginis Journal: J Vasc Interv Radiol Date: 2004-06 Impact factor: 3.464
Authors: Terri Jabaley; Niya Xiong; Susanne Conley; Teresa Mazeika; Danielle Johnson; Brenda A Biggins; Nancy Hilton; Fangxin Hong Journal: Can Oncol Nurs J Date: 2022-04-01
Authors: Terri Jabaley; Niya Xiong; Susanne Conley; Teresa Mazeika; Danielle Johnson; Brenda A Biggins; Nancy Hilton; Fangxin Hong Journal: Can Oncol Nurs J Date: 2022-04-01